Estimation of Coronavirus's impact on Vitrolife's sales
Vitrolife estimates that sales in the Asia region will decrease by approximately 30 percent in the first quarter and that the vast majority of patients scheduled to undergo IVF treatments in the first quarter will complete these at a later date.In conjunction with the report on operations, Vitrolife informed that the Corona virus was considered to have a negative impact on sales to China during the first quarter as a result of reduced demand. Vitrolife can now assess the effect of the Corona virus on the company's sales in the first quarter and estimates that sales in the Asia region will